Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02191137 · ClinicalTrials.gov registry record · Phase 4
Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)
A Phase 4 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 4
- Development phase
- 75
- Enrollment target
NCT02191137 is a Phase 4 study that has completed, run by Bayer. The registered enrollment target is 75 participants.
The verdict
NCT02191137, a Phase 4 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 75 participants
- Enrollment target
Study Summary
The MOTION study was a prospective, Phase IV study for patients with Pulmonary Arterial Hypertension (PAH). The study was designed to further explore patient-reported outcomes in PAH subjects who were not on active treatment and living in the United States. In addition, the study explored the use of new telemetric technology (Accelerator band) to evaluate if this technology correlates with improvements in 6 Minute Walking Distance 6MWD in patients with PAH.
Interventions
- DRUG Riociguat (Adempas, BAY63-2521)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2014-09-23 |
| Est. Completion | 2016-07-16 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02191137
The ClinicalTrials.gov registry entry for NCT02191137 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Riociguat (Adempas, BAY63-2521) is the first listed.
NCT02191137 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02191137 about?
NCT02191137 is a clinical study titled "Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)". The MOTION study was a prospective, Phase IV study for patients with Pulmonary Arterial Hypertension (PAH). The study was designed to further explore patient-reported outcomes in PAH subjects who were not on active treatment and living in the United States. In addition, the study explored the use of...
What is the current status of trial NCT02191137?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 75 participants. The study started on 2014-09-23. Estimated completion is 2016-07-16.
What interventions are being tested in trial NCT02191137?
The interventions under investigation include: Riociguat (Adempas, BAY63-2521) (DRUG).
Who is sponsoring clinical trial NCT02191137?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.